| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Transplantation | 69 | 2020 | 353 | 13.580 |
Why?
|
| Pancreas Transplantation | 42 | 2018 | 80 | 9.630 |
Why?
|
| Tissue Donors | 30 | 2018 | 167 | 6.410 |
Why?
|
| Graft Rejection | 35 | 2019 | 149 | 5.590 |
Why?
|
| Graft Survival | 32 | 2020 | 228 | 3.690 |
Why?
|
| Immunosuppressive Agents | 22 | 2019 | 167 | 3.620 |
Why?
|
| Tissue and Organ Procurement | 13 | 2018 | 69 | 3.210 |
Why?
|
| Delayed Graft Function | 9 | 2020 | 33 | 2.800 |
Why?
|
| Immunosuppression | 16 | 2019 | 80 | 2.730 |
Why?
|
| Kidney Failure, Chronic | 15 | 2018 | 519 | 2.580 |
Why?
|
| Antilymphocyte Serum | 8 | 2015 | 17 | 1.820 |
Why?
|
| Donor Selection | 4 | 2019 | 31 | 1.690 |
Why?
|
| Humans | 114 | 2020 | 29220 | 1.570 |
Why?
|
| Retrospective Studies | 31 | 2019 | 3122 | 1.530 |
Why?
|
| Kidney | 14 | 2020 | 486 | 1.460 |
Why?
|
| Organ Preservation | 6 | 2014 | 13 | 1.400 |
Why?
|
| Regenerative Medicine | 12 | 2015 | 187 | 1.370 |
Why?
|
| Tissue and Organ Harvesting | 6 | 2014 | 35 | 1.350 |
Why?
|
| Antibodies, Monoclonal | 8 | 2009 | 196 | 1.340 |
Why?
|
| Adult | 46 | 2020 | 8468 | 1.340 |
Why?
|
| Middle Aged | 50 | 2020 | 10872 | 1.300 |
Why?
|
| Regeneration | 10 | 2016 | 167 | 1.260 |
Why?
|
| Organ Transplantation | 8 | 2013 | 65 | 1.230 |
Why?
|
| Cadaver | 12 | 2018 | 143 | 1.180 |
Why?
|
| Male | 54 | 2020 | 17876 | 1.170 |
Why?
|
| Female | 55 | 2020 | 18241 | 1.130 |
Why?
|
| Nephrectomy | 5 | 2019 | 114 | 1.110 |
Why?
|
| Tissue Engineering | 10 | 2016 | 608 | 1.050 |
Why?
|
| Postoperative Complications | 7 | 2018 | 670 | 1.040 |
Why?
|
| Follow-Up Studies | 16 | 2019 | 2114 | 0.970 |
Why?
|
| Survival Rate | 11 | 2018 | 795 | 0.920 |
Why?
|
| Patient Selection | 8 | 2018 | 257 | 0.910 |
Why?
|
| Transplantation, Homologous | 10 | 2014 | 113 | 0.900 |
Why?
|
| Diabetes Mellitus | 3 | 2015 | 370 | 0.880 |
Why?
|
| Liver Transplantation | 13 | 2012 | 111 | 0.850 |
Why?
|
| Tissue Scaffolds | 12 | 2016 | 386 | 0.850 |
Why?
|
| Time Factors | 19 | 2017 | 2003 | 0.840 |
Why?
|
| Cytomegalovirus Infections | 5 | 2014 | 25 | 0.810 |
Why?
|
| Extracellular Matrix | 9 | 2016 | 226 | 0.800 |
Why?
|
| C-Peptide | 3 | 2018 | 25 | 0.780 |
Why?
|
| Isoantibodies | 3 | 2014 | 10 | 0.770 |
Why?
|
| Mycophenolic Acid | 6 | 2008 | 28 | 0.770 |
Why?
|
| Bioengineering | 9 | 2015 | 67 | 0.760 |
Why?
|
| Cold Ischemia | 2 | 2018 | 7 | 0.740 |
Why?
|
| Treatment Outcome | 21 | 2017 | 3108 | 0.730 |
Why?
|
| Extracorporeal Circulation | 2 | 2011 | 11 | 0.720 |
Why?
|
| Tacrolimus | 10 | 2008 | 44 | 0.710 |
Why?
|
| Living Donors | 5 | 2015 | 55 | 0.710 |
Why?
|
| Immunoglobulin G | 4 | 2004 | 104 | 0.710 |
Why?
|
| Diabetes Mellitus, Type 1 | 10 | 2014 | 180 | 0.710 |
Why?
|
| Portal Vein | 2 | 2013 | 16 | 0.700 |
Why?
|
| Antibodies, Neoplasm | 3 | 2009 | 12 | 0.700 |
Why?
|
| Aged | 20 | 2019 | 9515 | 0.690 |
Why?
|
| Steroids | 3 | 2015 | 36 | 0.680 |
Why?
|
| Prognosis | 9 | 2018 | 1363 | 0.660 |
Why?
|
| Endarterectomy | 1 | 2018 | 7 | 0.660 |
Why?
|
| Renal Artery | 1 | 2018 | 43 | 0.650 |
Why?
|
| Antiviral Agents | 5 | 2010 | 100 | 0.640 |
Why?
|
| Health Services Accessibility | 3 | 2017 | 231 | 0.640 |
Why?
|
| Risk Factors | 14 | 2018 | 3550 | 0.630 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2019 | 109 | 0.560 |
Why?
|
| Young Adult | 9 | 2019 | 2413 | 0.530 |
Why?
|
| Renal Insufficiency | 2 | 2017 | 53 | 0.530 |
Why?
|
| Kidney Neoplasms | 2 | 2019 | 192 | 0.520 |
Why?
|
| Drainage | 2 | 2013 | 49 | 0.520 |
Why?
|
| Uremia | 1 | 2015 | 9 | 0.520 |
Why?
|
| Kidney Diseases | 3 | 2014 | 239 | 0.520 |
Why?
|
| Embolization, Therapeutic | 2 | 2019 | 79 | 0.520 |
Why?
|
| Ganciclovir | 4 | 2008 | 14 | 0.510 |
Why?
|
| Transplantation Conditioning | 1 | 2014 | 11 | 0.510 |
Why?
|
| Pancreas | 6 | 2016 | 79 | 0.500 |
Why?
|
| Radiography, Interventional | 1 | 2014 | 35 | 0.500 |
Why?
|
| Ossification, Heterotopic | 1 | 2014 | 14 | 0.490 |
Why?
|
| Glomerular Filtration Rate | 6 | 2018 | 287 | 0.490 |
Why?
|
| Gastrointestinal Tract | 3 | 2012 | 29 | 0.480 |
Why?
|
| North Carolina | 6 | 2018 | 1425 | 0.460 |
Why?
|
| Animals | 18 | 2015 | 7302 | 0.460 |
Why?
|
| Perfusion | 4 | 2015 | 64 | 0.440 |
Why?
|
| Catheter Ablation | 1 | 2013 | 62 | 0.430 |
Why?
|
| Incidence | 6 | 2018 | 1123 | 0.430 |
Why?
|
| Azathioprine | 3 | 2011 | 8 | 0.420 |
Why?
|
| Polyomavirus Infections | 4 | 2006 | 21 | 0.420 |
Why?
|
| Death, Sudden, Cardiac | 2 | 2020 | 59 | 0.420 |
Why?
|
| Adolescent | 9 | 2019 | 3265 | 0.420 |
Why?
|
| Death | 2 | 2009 | 41 | 0.410 |
Why?
|
| Age Factors | 7 | 2019 | 1110 | 0.410 |
Why?
|
| Transplantation Tolerance | 1 | 2011 | 14 | 0.410 |
Why?
|
| Kidney Function Tests | 3 | 2018 | 102 | 0.410 |
Why?
|
| Reoperation | 6 | 2019 | 203 | 0.410 |
Why?
|
| Gout | 1 | 2011 | 14 | 0.410 |
Why?
|
| Thiazoles | 1 | 2011 | 32 | 0.410 |
Why?
|
| Thrombosis | 1 | 2012 | 60 | 0.400 |
Why?
|
| Fibrinolytic Agents | 1 | 2012 | 70 | 0.400 |
Why?
|
| Thrombectomy | 1 | 2012 | 58 | 0.400 |
Why?
|
| Heart Arrest | 1 | 2011 | 39 | 0.390 |
Why?
|
| Anticoagulants | 1 | 2012 | 122 | 0.390 |
Why?
|
| Sirolimus | 3 | 2008 | 35 | 0.370 |
Why?
|
| Prospective Studies | 6 | 2018 | 2027 | 0.350 |
Why?
|
| Creatinine | 5 | 2016 | 174 | 0.350 |
Why?
|
| Islets of Langerhans Transplantation | 4 | 2014 | 40 | 0.340 |
Why?
|
| Blood Group Incompatibility | 3 | 2016 | 11 | 0.330 |
Why?
|
| ABO Blood-Group System | 3 | 2016 | 19 | 0.330 |
Why?
|
| Insulin | 4 | 2018 | 346 | 0.290 |
Why?
|
| Child, Preschool | 4 | 2019 | 1168 | 0.290 |
Why?
|
| Tumor Virus Infections | 2 | 2004 | 20 | 0.280 |
Why?
|
| Survival Analysis | 7 | 2019 | 440 | 0.280 |
Why?
|
| Stem Cell Transplantation | 5 | 2015 | 203 | 0.280 |
Why?
|
| Anemia, Hemolytic | 1 | 2005 | 6 | 0.270 |
Why?
|
| United States | 7 | 2017 | 3648 | 0.270 |
Why?
|
| Erythrocytes | 1 | 2005 | 43 | 0.270 |
Why?
|
| Rabbits | 3 | 2014 | 185 | 0.260 |
Why?
|
| Hypertension | 1 | 2011 | 913 | 0.240 |
Why?
|
| Diabetic Nephropathies | 1 | 2005 | 195 | 0.240 |
Why?
|
| Infant | 4 | 2019 | 973 | 0.230 |
Why?
|
| Nephritis, Interstitial | 1 | 2003 | 9 | 0.230 |
Why?
|
| Hepatitis C | 2 | 2019 | 38 | 0.220 |
Why?
|
| Prednisone | 1 | 2002 | 43 | 0.210 |
Why?
|
| Registries | 2 | 2016 | 280 | 0.210 |
Why?
|
| Academic Medical Centers | 1 | 2003 | 150 | 0.210 |
Why?
|
| Postoperative Period | 2 | 2014 | 91 | 0.200 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2002 | 90 | 0.200 |
Why?
|
| Child | 3 | 2019 | 2221 | 0.190 |
Why?
|
| Chi-Square Distribution | 3 | 2017 | 293 | 0.190 |
Why?
|
| Length of Stay | 2 | 2014 | 294 | 0.190 |
Why?
|
| Cyclosporine | 5 | 1993 | 34 | 0.180 |
Why?
|
| RNA | 1 | 2020 | 88 | 0.170 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 3728 | 0.170 |
Why?
|
| Antibodies | 1 | 1998 | 53 | 0.170 |
Why?
|
| Acyclovir | 1 | 1998 | 8 | 0.160 |
Why?
|
| Hypoglycemia | 1 | 1998 | 41 | 0.160 |
Why?
|
| Gene Expression Profiling | 1 | 2020 | 320 | 0.160 |
Why?
|
| Treatment Failure | 2 | 2017 | 159 | 0.160 |
Why?
|
| Biopsy | 4 | 2014 | 241 | 0.160 |
Why?
|
| Cohort Studies | 3 | 2011 | 1695 | 0.160 |
Why?
|
| Odds Ratio | 2 | 2016 | 448 | 0.150 |
Why?
|
| Apolipoproteins | 2 | 2016 | 196 | 0.150 |
Why?
|
| Blood Transfusion | 2 | 2014 | 64 | 0.140 |
Why?
|
| Islets of Langerhans | 2 | 2016 | 75 | 0.140 |
Why?
|
| Lipoproteins, HDL | 2 | 2016 | 247 | 0.140 |
Why?
|
| Bioreactors | 2 | 2013 | 59 | 0.140 |
Why?
|
| Microvessels | 1 | 2015 | 23 | 0.130 |
Why?
|
| Healthcare Disparities | 1 | 2017 | 153 | 0.130 |
Why?
|
| Kidney Glomerulus | 1 | 2015 | 30 | 0.130 |
Why?
|
| Caveolin 1 | 1 | 2015 | 13 | 0.130 |
Why?
|
| Brain Death | 2 | 2014 | 27 | 0.130 |
Why?
|
| Preoperative Period | 1 | 2014 | 31 | 0.130 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2015 | 100 | 0.130 |
Why?
|
| Hemodynamics | 1 | 2015 | 148 | 0.130 |
Why?
|
| Metaplasia | 1 | 2014 | 20 | 0.130 |
Why?
|
| HLA Antigens | 2 | 2014 | 35 | 0.130 |
Why?
|
| Blood Loss, Surgical | 1 | 2014 | 45 | 0.130 |
Why?
|
| Immune Tolerance | 2 | 2014 | 67 | 0.120 |
Why?
|
| Insulin-Secreting Cells | 1 | 2014 | 53 | 0.120 |
Why?
|
| Bioprosthesis | 1 | 2014 | 55 | 0.120 |
Why?
|
| Acute Disease | 4 | 2012 | 239 | 0.120 |
Why?
|
| Preoperative Care | 1 | 2014 | 110 | 0.120 |
Why?
|
| Regional Blood Flow | 1 | 2013 | 82 | 0.120 |
Why?
|
| Organ Culture Techniques | 1 | 2013 | 38 | 0.120 |
Why?
|
| Insurance Coverage | 1 | 2013 | 74 | 0.110 |
Why?
|
| Disease Progression | 1 | 2014 | 572 | 0.110 |
Why?
|
| Abdomen | 1 | 2012 | 42 | 0.110 |
Why?
|
| Intestines | 2 | 2010 | 54 | 0.110 |
Why?
|
| Kidney Tubular Necrosis, Acute | 1 | 1992 | 2 | 0.110 |
Why?
|
| Liver | 2 | 2012 | 464 | 0.110 |
Why?
|
| Drug Administration Schedule | 2 | 2003 | 246 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2011 | 1383 | 0.110 |
Why?
|
| Waiting Lists | 2 | 2013 | 30 | 0.110 |
Why?
|
| Cells, Cultured | 1 | 2014 | 800 | 0.110 |
Why?
|
| Blood Grouping and Crossmatching | 2 | 2016 | 9 | 0.100 |
Why?
|
| Warfarin | 1 | 2012 | 30 | 0.100 |
Why?
|
| Postoperative Hemorrhage | 1 | 2012 | 38 | 0.100 |
Why?
|
| Gastrointestinal Diseases | 1 | 2012 | 38 | 0.100 |
Why?
|
| Gout Suppressants | 1 | 2011 | 4 | 0.100 |
Why?
|
| Aspirin | 1 | 2012 | 62 | 0.100 |
Why?
|
| Drug Therapy, Combination | 2 | 2003 | 273 | 0.100 |
Why?
|
| Hepatitis, Viral, Human | 1 | 1991 | 4 | 0.100 |
Why?
|
| Heparin | 1 | 2012 | 75 | 0.100 |
Why?
|
| African Americans | 2 | 2016 | 1373 | 0.100 |
Why?
|
| Drug Interactions | 1 | 2011 | 80 | 0.100 |
Why?
|
| General Surgery | 1 | 2012 | 81 | 0.100 |
Why?
|
| Warm Ischemia | 1 | 2011 | 8 | 0.100 |
Why?
|
| Transplantation Immunology | 4 | 2015 | 27 | 0.100 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2015 | 1079 | 0.100 |
Why?
|
| Ethnic Groups | 1 | 2013 | 440 | 0.100 |
Why?
|
| Cost-Benefit Analysis | 1 | 2010 | 160 | 0.090 |
Why?
|
| Immunotherapy | 1 | 2010 | 69 | 0.090 |
Why?
|
| Proportional Hazards Models | 3 | 2017 | 710 | 0.090 |
Why?
|
| Serum Albumin | 1 | 2010 | 53 | 0.090 |
Why?
|
| Solutions | 1 | 2009 | 26 | 0.090 |
Why?
|
| Stem Cells | 4 | 2014 | 292 | 0.090 |
Why?
|
| Hyperglycemia | 1 | 2010 | 82 | 0.090 |
Why?
|
| Risk Assessment | 2 | 2017 | 1313 | 0.090 |
Why?
|
| Glomerulonephritis, IGA | 1 | 2009 | 6 | 0.090 |
Why?
|
| Asphyxia | 1 | 2009 | 6 | 0.090 |
Why?
|
| Infarction | 1 | 2009 | 5 | 0.090 |
Why?
|
| Suicide | 1 | 2009 | 17 | 0.090 |
Why?
|
| Leukopenia | 1 | 2008 | 7 | 0.080 |
Why?
|
| T-Lymphocytes | 1 | 2009 | 116 | 0.080 |
Why?
|
| Cause of Death | 2 | 2007 | 220 | 0.080 |
Why?
|
| Ischemia | 1 | 2009 | 92 | 0.080 |
Why?
|
| Compartment Syndromes | 1 | 2009 | 38 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2011 | 466 | 0.080 |
Why?
|
| Diabetes Complications | 1 | 2010 | 171 | 0.080 |
Why?
|
| Inflammation | 1 | 2012 | 508 | 0.080 |
Why?
|
| Intraoperative Period | 1 | 2007 | 37 | 0.080 |
Why?
|
| Case-Control Studies | 2 | 2007 | 860 | 0.080 |
Why?
|
| Age Distribution | 1 | 2007 | 198 | 0.070 |
Why?
|
| Cryopreservation | 1 | 2007 | 42 | 0.070 |
Why?
|
| Body Size | 1 | 2006 | 31 | 0.070 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 638 | 0.070 |
Why?
|
| Nephrons | 1 | 2006 | 10 | 0.070 |
Why?
|
| Polyomavirus | 1 | 2006 | 1 | 0.070 |
Why?
|
| Rho(D) Immune Globulin | 1 | 2005 | 2 | 0.070 |
Why?
|
| Glycosuria, Renal | 1 | 2005 | 3 | 0.070 |
Why?
|
| Hemolysis | 1 | 2005 | 12 | 0.070 |
Why?
|
| Anastomosis, Surgical | 2 | 2003 | 49 | 0.070 |
Why?
|
| Organogenesis | 2 | 2016 | 15 | 0.070 |
Why?
|
| Lymphocytes | 1 | 2005 | 53 | 0.070 |
Why?
|
| Quality of Health Care | 1 | 2006 | 134 | 0.070 |
Why?
|
| Drug Monitoring | 1 | 2004 | 24 | 0.060 |
Why?
|
| BK Virus | 1 | 2004 | 7 | 0.060 |
Why?
|
| Phenotype | 2 | 2016 | 629 | 0.060 |
Why?
|
| Portal System | 1 | 2003 | 6 | 0.060 |
Why?
|
| Attitude to Health | 1 | 2004 | 148 | 0.060 |
Why?
|
| Triglycerides | 1 | 2004 | 214 | 0.060 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2003 | 20 | 0.060 |
Why?
|
| Transplants | 2 | 2014 | 22 | 0.060 |
Why?
|
| Liver Regeneration | 2 | 2012 | 23 | 0.050 |
Why?
|
| Cholesterol | 1 | 2004 | 230 | 0.050 |
Why?
|
| Muromonab-CD3 | 4 | 2002 | 5 | 0.050 |
Why?
|
| Quality of Life | 3 | 2015 | 820 | 0.050 |
Why?
|
| Bile Ducts | 1 | 2001 | 18 | 0.050 |
Why?
|
| Histocompatibility Testing | 2 | 2014 | 15 | 0.050 |
Why?
|
| Biocompatible Materials | 2 | 2012 | 210 | 0.050 |
Why?
|
| Cold Temperature | 1 | 2001 | 39 | 0.050 |
Why?
|
| Databases, Factual | 2 | 2017 | 333 | 0.050 |
Why?
|
| Long-Term Care | 1 | 2000 | 21 | 0.050 |
Why?
|
| Remission, Spontaneous | 1 | 2019 | 14 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2019 | 49 | 0.040 |
Why?
|
| Angiography | 1 | 2019 | 75 | 0.040 |
Why?
|
| Hepacivirus | 1 | 2019 | 37 | 0.040 |
Why?
|
| Viral Load | 1 | 2019 | 67 | 0.040 |
Why?
|
| Tennessee | 1 | 1998 | 97 | 0.040 |
Why?
|
| Costs and Cost Analysis | 1 | 1998 | 88 | 0.040 |
Why?
|
| Administration, Oral | 1 | 1998 | 169 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 437 | 0.040 |
Why?
|
| Blood Glucose | 1 | 1998 | 467 | 0.030 |
Why?
|
| Protein Array Analysis | 1 | 2015 | 16 | 0.030 |
Why?
|
| Corrosion Casting | 1 | 2015 | 9 | 0.030 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2015 | 20 | 0.030 |
Why?
|
| Social Support | 1 | 2017 | 164 | 0.030 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2015 | 92 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2015 | 103 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 148 | 0.030 |
Why?
|
| Haplotypes | 1 | 2015 | 220 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2019 | 871 | 0.030 |
Why?
|
| Genotype | 1 | 2016 | 735 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 1998 | 1366 | 0.030 |
Why?
|
| Forecasting | 1 | 2014 | 133 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 1219 | 0.030 |
Why?
|
| Antigens | 1 | 2013 | 31 | 0.030 |
Why?
|
| Detergents | 1 | 2013 | 17 | 0.030 |
Why?
|
| Chickens | 1 | 2013 | 40 | 0.030 |
Why?
|
| Pressure | 1 | 2013 | 54 | 0.030 |
Why?
|
| Sus scrofa | 1 | 2013 | 44 | 0.030 |
Why?
|
| Quality Assurance, Health Care | 2 | 2004 | 62 | 0.030 |
Why?
|
| Capsules | 1 | 2012 | 14 | 0.030 |
Why?
|
| Neovascularization, Physiologic | 1 | 2013 | 106 | 0.030 |
Why?
|
| Renal Circulation | 1 | 1992 | 13 | 0.030 |
Why?
|
| Skin, Artificial | 1 | 2012 | 31 | 0.030 |
Why?
|
| Larynx | 1 | 2012 | 19 | 0.030 |
Why?
|
| Chondroitin Sulfates | 1 | 2012 | 22 | 0.030 |
Why?
|
| Hepatocytes | 1 | 2012 | 74 | 0.030 |
Why?
|
| Vascular Resistance | 1 | 1992 | 28 | 0.030 |
Why?
|
| Respiratory Tract Diseases | 1 | 2012 | 30 | 0.030 |
Why?
|
| Pancreatic Diseases | 1 | 2012 | 16 | 0.030 |
Why?
|
| Liver Failure | 1 | 2012 | 17 | 0.030 |
Why?
|
| Intestinal Diseases | 1 | 2012 | 18 | 0.030 |
Why?
|
| Dogs | 1 | 1992 | 117 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2014 | 436 | 0.030 |
Why?
|
| Swine | 1 | 2012 | 201 | 0.030 |
Why?
|
| Cell Transplantation | 1 | 2012 | 63 | 0.030 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2012 | 78 | 0.030 |
Why?
|
| Developmental Biology | 1 | 2011 | 7 | 0.030 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1991 | 5 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2013 | 519 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 1991 | 21 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 1991 | 22 | 0.030 |
Why?
|
| Cattle | 1 | 2011 | 100 | 0.020 |
Why?
|
| History, 20th Century | 1 | 2011 | 68 | 0.020 |
Why?
|
| Corneal Transplantation | 1 | 2010 | 13 | 0.020 |
Why?
|
| Collagen | 1 | 2012 | 217 | 0.020 |
Why?
|
| Chondrocytes | 1 | 2011 | 71 | 0.020 |
Why?
|
| Wound Healing | 1 | 2012 | 182 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2013 | 573 | 0.020 |
Why?
|
| European Continental Ancestry Group | 1 | 2015 | 1131 | 0.020 |
Why?
|
| Trachea | 1 | 2010 | 55 | 0.020 |
Why?
|
| Ultrasonography | 1 | 1992 | 347 | 0.020 |
Why?
|
| Heart | 1 | 2010 | 162 | 0.020 |
Why?
|
| Wounds and Injuries | 1 | 2012 | 251 | 0.020 |
Why?
|
| Transplantation | 1 | 1989 | 12 | 0.020 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2008 | 21 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2010 | 177 | 0.020 |
Why?
|
| Models, Biological | 1 | 2010 | 373 | 0.020 |
Why?
|
| Chronic Disease | 3 | 1993 | 370 | 0.020 |
Why?
|
| Sex Factors | 2 | 2004 | 632 | 0.020 |
Why?
|
| Heart Failure | 1 | 2012 | 573 | 0.020 |
Why?
|
| Necrosis | 1 | 2006 | 53 | 0.020 |
Why?
|
| Drug Therapy | 1 | 2006 | 16 | 0.020 |
Why?
|
| Mice | 1 | 2011 | 2372 | 0.020 |
Why?
|
| Disease Management | 1 | 2006 | 114 | 0.020 |
Why?
|
| Factor Analysis, Statistical | 1 | 2004 | 70 | 0.020 |
Why?
|
| Heart Transplantation | 1 | 2004 | 26 | 0.020 |
Why?
|
| Needs Assessment | 1 | 2004 | 66 | 0.020 |
Why?
|
| Health Surveys | 1 | 2004 | 191 | 0.010 |
Why?
|
| Psychometrics | 1 | 2004 | 129 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2008 | 546 | 0.010 |
Why?
|
| Liver Function Tests | 2 | 1993 | 19 | 0.010 |
Why?
|
| Morbidity | 1 | 2002 | 92 | 0.010 |
Why?
|
| Mortality | 1 | 2003 | 109 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2002 | 281 | 0.010 |
Why?
|
| Adrenal Cortex Hormones | 2 | 1993 | 148 | 0.010 |
Why?
|
| Risk | 1 | 2002 | 290 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2004 | 864 | 0.010 |
Why?
|
| Hepatectomy | 1 | 2001 | 66 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 1993 | 4 | 0.010 |
Why?
|
| Bilirubin | 1 | 1993 | 22 | 0.010 |
Why?
|
| Communicable Diseases | 1 | 1993 | 19 | 0.010 |
Why?
|
| Drug Resistance | 1 | 1993 | 36 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 1993 | 167 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1993 | 454 | 0.010 |
Why?
|
| Renal Dialysis | 1 | 1993 | 261 | 0.010 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 1989 | 3 | 0.010 |
Why?
|
| Wisconsin | 1 | 1989 | 18 | 0.010 |
Why?
|
| California | 1 | 1989 | 60 | 0.010 |
Why?
|
| Pregnancy | 1 | 1989 | 816 | 0.000 |
Why?
|